卢旺达南部疟原虫 Kelch13 多态性增加。
Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda.
出版信息
Emerg Infect Dis. 2021 Jan;27(1):294-296. doi: 10.3201/eid2701.203527.
Abstract
Artemisinin resistance in Plasmodium falciparum is associated with nonsynonymous mutations in the Kelch 13 (K13) propeller domain. We found that 12.1% (8/66) of clinical P. falciparum isolates from Huye district, Rwanda, exhibited K13 mutations, including R561H, a validated resistance marker. K13 mutations appear to be increasing in this region.
摘要
青蒿素抗药性在恶性疟原虫中与半胱氨酸蛋白酶 13（Kelch 13，K13）的螺旋桨结构域中的非同义突变有关。我们发现，来自卢旺达胡耶区的 66 例临床疟原虫分离株中有 12.1%（8/66）出现 K13 突变，包括已证实的耐药标志物 R561H。该地区的 K13 突变似乎正在增加。
相似文献
1
Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda.
Emerg Infect Dis. 2021 Jan;27(1):294-296. doi: 10.3201/eid2701.203527.
2
In Vitro Confirmation of Artemisinin Resistance in Plasmodium falciparum from Patient Isolates, Southern Rwanda, 2019.
Emerg Infect Dis. 2022 Apr;28(4):852-855. doi: 10.3201/eid2804.212269.
3
Escalating marker prevalence indicative of artemisinin resistance in southern Rwanda.
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0129923. doi: 10.1128/aac.01299-23. Epub 2023 Dec 11.
4
Artemisinin Resistance-Associated K13 Polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010-2015.
Am J Trop Med Hyg. 2016 Nov 2;95(5):1090-1093. doi: 10.4269/ajtmh.16-0483. Epub 2016 Aug 29.
5
Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda.
Malar J. 2024 May 16;23(1):150. doi: 10.1186/s12936-024-04981-4.
6
High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
J Infect Dis. 2022 Apr 19;225(8):1411-1414. doi: 10.1093/infdis/jiab352.
7
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.
Nat Med. 2020 Oct;26(10):1602-1608. doi: 10.1038/s41591-020-1005-2. Epub 2020 Aug 3.
8
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.
Lancet Infect Dis. 2021 Aug;21(8):1120-1128. doi: 10.1016/S1473-3099(21)00142-0. Epub 2021 Apr 14.
9
K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness.
Elife. 2021 Jul 19;10:e66277. doi: 10.7554/eLife.66277.
10
No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of Congo.
BMC Infect Dis. 2018 Oct 29;18(1):538. doi: 10.1186/s12879-018-3453-6.
引用本文的文献
1
Investigating the relationship between mutations and response to artemisinin-based treatment for uncomplicated falciparum malaria: a protocol for a systematic review and individual patient data meta-analysis.
BMJ Open. 2025 Jul 8;15(7):e100251. doi: 10.1136/bmjopen-2025-100251.
2
Malaria: past, present, and future.
Signal Transduct Target Ther. 2025 Jun 17;10(1):188. doi: 10.1038/s41392-025-02246-3.
3
A Narrative Review on the Prevalence of Resistance Mutations to Antimalarial Drugs in Rwanda.
Trop Med Infect Dis. 2025 Mar 29;10(4):89. doi: 10.3390/tropicalmed10040089.
4
Half-decade of scaling up malaria control: malaria trends and impact of interventions from 2018 to 2023 in Rwanda.
Malar J. 2025 Feb 12;24(1):40. doi: 10.1186/s12936-025-05278-w.
5
Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.
Nat Commun. 2024 Jun 18;15(1):5219. doi: 10.1038/s41467-024-49491-8.
6
Therapeutic efficacy and safety of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria treatment in Metehara, Central-east Ethiopia.
Malar J. 2024 Jun 12;23(1):184. doi: 10.1186/s12936-024-04991-2.
7
Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda.
Malar J. 2024 May 16;23(1):150. doi: 10.1186/s12936-024-04981-4.
8
High frequency of artemisinin partial resistance mutations in the great lake region revealed through rapid pooled deep sequencing.
medRxiv. 2024 May 1:2024.04.29.24306442. doi: 10.1101/2024.04.29.24306442.
9
The Walter Reed Project, Kisumu Field Station: Impact of Research on Malaria Policy, Management, and Prevention.
Am J Trop Med Hyg. 2024 Apr 23;110(6):1069-1079. doi: 10.4269/ajtmh.23-0115. Print 2024 Jun 5.
10
Spatio-temporal spread of artemisinin resistance in Southeast Asia.
PLoS Comput Biol. 2024 Apr 16;20(4):e1012017. doi: 10.1371/journal.pcbi.1012017. eCollection 2024 Apr.
本文引用的文献
1
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.
Nat Med. 2020 Oct;26(10):1602-1608. doi: 10.1038/s41591-020-1005-2. Epub 2020 Aug 3.
2
The Diversity of the K13 Propeller Domain Did Not Increase after Implementation of Artemisinin-Based Combination Therapy in Uganda.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01234-19. Print 2019 Oct.
3
K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors.
Malar J. 2019 Mar 7;18(1):60. doi: 10.1186/s12936-019-2701-6.
4
Expanding home-based management of malaria to all age groups in Rwanda: analysis of acceptability and facility-level time-series data.
Trans R Soc Trop Med Hyg. 2018 Nov 1;112(11):513-521. doi: 10.1093/trstmh/try093.
5
Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014-2016.
Emerg Infect Dis. 2018 Apr;24(4):718-726. doi: 10.3201/eid2404.170141.
6
The threat of antimalarial drug resistance.
Trop Dis Travel Med Vaccines. 2016 Jul 7;2:10. doi: 10.1186/s40794-016-0027-8. eCollection 2016.
7
Host immunity to and the assessment of emerging artemisinin resistance in a multinational cohort.
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520. doi: 10.1073/pnas.1615875114. Epub 2017 Mar 13.
8
Artemisinin Resistance-Associated K13 Polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010-2015.
Am J Trop Med Hyg. 2016 Nov 2;95(5):1090-1093. doi: 10.4269/ajtmh.16-0483. Epub 2016 Aug 29.
9
A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.
N Engl J Med. 2016 Jun 23;374(25):2453-64. doi: 10.1056/NEJMoa1513137.
10
Genomic epidemiology of artemisinin resistant malaria.
Elife. 2016 Mar 4;5:e08714. doi: 10.7554/eLife.08714.
Zotero 插件